

**7 February 2020**

To,  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

To,  
**National Stock Exchange of India Limited**  
Exchange Plaza,  
Bandra - Kurla Complex,  
Bandra (E), Mumbai - 400 051

Scrip Code: 524669

Symbol: HESTERBIO

**Respected Sir / Madam,**

**Subject: Outcome of Board Meeting held today and Submission of Standalone and Consolidated Unaudited Financial Results for the quarter and nine months ended on 31 December 2019**

**Start Time: 10.30 am**

**Conclusion Time: 11.10 am**

This is with reference to our letter dated 27 January 2020 intimating the date of the Board Meeting for consideration of the Standalone and Consolidated Unaudited Financial Results for the quarter and nine months ended on 31 December 2019.

Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of Directors, in their Meeting held today, have approved the followings:

- 1) Standalone and Consolidated Unaudited Financial Results for the quarter and nine months ended on 31 December 2019.
- 2) Agreement with NOVAPHARMA for Technical Collaboration & Licensing to provide technology and support to set up an animal vaccines manufacturing facility in Egypt.

We attach herewith:

- 1) The approved Standalone and Consolidated Unaudited Financial Results along with Limited Review Report
- 2) Press Release issued in this regard

We would be publishing the extract of results in the newspaper as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

You are requested to take the above information on your record.

**Sincerely,**  
**For Hester Biosciences Limited**



**Rajiv Gandhi**  
**CEO & Managing Director**  
DIN: 00438037